Go Deep
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,475 | 36.5 | 7.39 | 0.31 | 1,927.80 |
| Sep 2026 | 21,475 | 36.5 | 7.39 | 0.31 | 1,927.80 |
| Oct 2026 | 21,116 | 36.5 | 7.45 | 0.31 | 1,944.60 |
| Oct 2026 | 20,743 | 34.4 | 7.03 | 0.31 | 1,833.50 |
Emcure Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 25,804,470,000.0 | 24,697,030,000.0 | 23,634,780,000.0 | 22,698,220,000.0 |
| Net Profit | 2,939,800,000.0 | 2,434,030,000.0 | 2,305,410,000.0 | 2,434,640,000.0 |
| EPS | 15.5 | 12.8 | 12.2 | 12.8 |
Emcure Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 91,158,880,000.0 | 78,082,710,000.0 | 65,819,920,000.0 | 59,310,760,000.0 | — |
| Net Profit | 9,243,610,000.0 | 6,813,320,000.0 | 4,981,830,000.0 | 5,320,190,000.0 | — |
| EPS | 48.8 | 36.4 | 27.6 | 29.4 | — |
Emcure Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 96,124,810,000.0 | 82,327,230,000.0 | 78,061,630,000.0 | 66,725,310,000.0 | — |
| Total Liabilities | 46,358,080,000.0 | 35,911,690,000.0 | 46,843,980,000.0 | 40,228,710,000.0 | — |
| Total Equity | 49,500,320,000.0 | 44,461,860,000.0 | 29,522,830,000.0 | 25,011,260,000.0 | — |
Owes vs Owns
Emcure Pharmaceuticals Limited owed ₹0.48 for every ₹1 it owned in Mar 2026, down from ₹0.60 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.48× | 0.44× | 0.60× | 0.60× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Emcure Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 1.1%Receivables 26.7%Inventory 24.9%Fixed assets (tangible) 26.8%Intangible assets 11.5%Other assets 8.8%
How it's funded — Mar 2026
Short-term debt 9.9%Long-term debt 2.6%Payables 18.8%Other liabilities 16.9%Shareholders' equity 51.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 103.2 | 197.9 | 398.2 | 260.8 |
| Receivables | 2,562.7 | 2,002.2 | 1,858.8 | 1,648.3 |
| Inventory | 2,397.9 | 1,931.8 | 1,525.1 | 1,383.0 |
| Fixed assets (tangible) | 2,576.1 | 2,444.0 | 2,411.3 | 2,230.8 |
| Intangible assets | 1,101.1 | 947.0 | 886.5 | 343.5 |
| Long-term investments | 21.7 | 21.0 | 18.7 | 55.8 |
| Other assets | 849.8 | 688.8 | 707.7 | 750.2 |
| Liabilities & equity | ||||
| Short-term debt | 951.9 | 541.8 | 1,320.7 | 1,450.8 |
| Long-term debt | 252.2 | 189.9 | 766.6 | 744.1 |
| Payables | 1,807.8 | 1,479.6 | 1,309.4 | 1,086.1 |
| Other liabilities | 1,624.0 | 1,379.9 | 1,287.7 | 741.8 |
| Shareholders' equity | 4,976.7 | 4,641.6 | 3,121.8 | 2,649.7 |
| Net tangible assets | 3,848.9 | 3,499.2 | 2,065.8 | 2,157.6 |
Emcure Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 9,435,450,000.0 | 8,517,050,000.0 | 10,972,400,000.0 | 7,468,530,000.0 | — |
| Investing Activities | -11,930,550,000.0 | -940,010,000.0 | -7,125,120,000.0 | -4,676,850,000.0 | — |
| Financing Activities | 3,434,310,000.0 | -8,139,570,000.0 | -1,642,060,000.0 | -1,453,970,000.0 | — |